AKRX earnings call for the period ending March 31, 2019.
News & Analysis: Akorn
The embattled generic-pharmaceutical manufacturer earned two new product approvals.
AKRX earnings call for the period ending December 31, 2018.
It looks as if the company's former suitor will get a chance to run from the altar.
A judge gave Fresenius the green light to walk away from the now-infamous merger.
Learn why these stocks missed the rally.
It's official: A judge ruled that Fresenius can abandon the previously announced acquisition of Akorn.
The rift with Fresenius continues to make headlines.
Investors received new details explaining why Fresenius dropped its acquisition. They aren't good.
The drama continues.